These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 9234533)

  • 21. Recombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4+ Th1 immune responses and are protective in mouse and guinea pig models of vaginal challenge.
    Natuk RJ; Cooper D; Guo M; Calderon P; Wright KJ; Nasar F; Witko S; Pawlyk D; Lee M; DeStefano J; Tummolo D; Abramovitz AS; Gangolli S; Kalyan N; Clarke DK; Hendry RM; Eldridge JH; Udem SA; Kowalski J
    J Virol; 2006 May; 80(9):4447-57. PubMed ID: 16611905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone.
    Awasthi S; Lubinski JM; Shaw CE; Barrett SM; Cai M; Wang F; Betts M; Kingsley S; Distefano DJ; Balliet JW; Flynn JA; Casimiro DR; Bryan JT; Friedman HM
    J Virol; 2011 Oct; 85(20):10472-86. PubMed ID: 21813597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs.
    Hoshino Y; Pesnicak L; Dowdell KC; Burbelo PD; Knipe DM; Straus SE; Cohen JI
    J Infect Dis; 2009 Oct; 200(7):1088-95. PubMed ID: 19702506
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs.
    Heineman TC; Connelly BL; Bourne N; Stanberry LR; Cohen J
    J Virol; 1995 Dec; 69(12):8109-13. PubMed ID: 7494331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread.
    Awasthi S; Zumbrun EE; Si H; Wang F; Shaw CE; Cai M; Lubinski JM; Barrett SM; Balliet JW; Flynn JA; Casimiro DR; Bryan JT; Friedman HM
    J Virol; 2012 Apr; 86(8):4586-98. PubMed ID: 22318147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital disease.
    Da Costa XJ; Bourne N; Stanberry LR; Knipe DM
    Virology; 1997 May; 232(1):1-12. PubMed ID: 9185583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protection provided by a herpes simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital HSV-2 infection in HSV-1-seropositive guinea pigs.
    Awasthi S; Balliet JW; Flynn JA; Lubinski JM; Shaw CE; DiStefano DJ; Cai M; Brown M; Smith JF; Kowalski R; Swoyer R; Galli J; Copeland V; Rios S; Davidson RC; Salnikova M; Kingsley S; Bryan J; Casimiro DR; Friedman HM
    J Virol; 2014 Feb; 88(4):2000-10. PubMed ID: 24284325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intranasal immunization with recombinant gD2 reduces disease severity and mortality following genital challenge with herpes simplex virus type 2 in guinea pigs.
    O'Hagan D; Goldbeck C; Ugozzoli M; Ott G; Burke RL
    Vaccine; 1999 May; 17(18):2229-36. PubMed ID: 10403590
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of the Herpes Simplex Virus 2 (HSV-2) Glycoprotein D/AS04 Vaccine against Genital HSV-2 and HSV-1 Infection and Disease in the Cotton Rat Sigmodon hispidus Model.
    Boukhvalova M; McKay J; Mbaye A; Sanford-Crane H; Blanco JC; Huber A; Herold BC
    J Virol; 2015 Oct; 89(19):9825-40. PubMed ID: 26178984
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection.
    Da Costa XJ; Morrison LA; Knipe DM
    Virology; 2001 Sep; 288(2):256-63. PubMed ID: 11601897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of mucosal immunity against herpes simplex virus by plasmid DNA immunization.
    Kuklin N; Daheshia M; Karem K; Manickan E; Rouse BT
    J Virol; 1997 Apr; 71(4):3138-45. PubMed ID: 9060677
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes.
    Stanberry LR; Bernstein DI; Burke RL; Pachl C; Myers MG
    J Infect Dis; 1987 May; 155(5):914-20. PubMed ID: 3031173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Herpes simplex virus DNA vaccine efficacy: effect of glycoprotein D plasmid constructs.
    Strasser JE; Arnold RL; Pachuk C; Higgins TJ; Bernstein DI
    J Infect Dis; 2000 Nov; 182(5):1304-10. PubMed ID: 11023454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease.
    Boursnell ME; Entwisle C; Blakeley D; Roberts C; Duncan IA; Chisholm SE; Martin GM; Jennings R; Ni Challanaín D; Sobek I; Inglis SC; McLean CS
    J Infect Dis; 1997 Jan; 175(1):16-25. PubMed ID: 8985191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected.
    Bourne N; Milligan GN; Stanberry LR; Stegall R; Pyles RB
    J Infect Dis; 2005 Dec; 192(12):2117-23. PubMed ID: 16288376
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs.
    Bourne N; Bravo FJ; Francotte M; Bernstein DI; Myers MG; Slaoui M; Stanberry LR
    J Infect Dis; 2003 Feb; 187(4):542-9. PubMed ID: 12599070
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A growth and latency compromised herpes simplex virus type 2 mutant (ICP10DeltaPK) has prophylactic and therapeutic protective activity in guinea pigs.
    Wachsman M; Kulka M; Smith CC; Aurelian L
    Vaccine; 2001 Feb; 19(15-16):1879-90. PubMed ID: 11228357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunization with a dominant-negative recombinant Herpes Simplex Virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigs.
    Brans R; Yao F
    BMC Microbiol; 2010 Jun; 10():163. PubMed ID: 20525279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of an immune enhancer, GPI-0100, on vaccination with live attenuated herpes simplex virus (HSV) type 2 or glycoprotein D on genital HSV-2 infections of guinea pigs.
    Quenelle DC; Collins DJ; Rice TL; Prichard MN; Marciani DJ; Kern ER
    Antiviral Res; 2008 Nov; 80(2):223-4. PubMed ID: 18573279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DNA immunization with a herpes simplex virus 2 bacterial artificial chromosome.
    Meseda CA; Schmeisser F; Pedersen R; Woerner A; Weir JP
    Virology; 2004 Jan; 318(1):420-8. PubMed ID: 14972567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.